CI Stock Analysis
💡 Quick Answer
Across 4 APEX technical signals, CI is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-06-11. Run a live analysis to see the current composite score.
CI has ATR of 2-3% and is the most defensively positioned large-cap health insurer. Its Evernorth PBM provides stable fee-based revenue regardless of medical cost trends.
Cigna is a global health insurance and pharmacy benefits company with two primary divisions: Evernorth Health Services (the PBM and specialty pharmacy business, including Express Scripts) and Cigna Healthcare (commercial and government health insurance). Evernorth is the largest PBM in the U.S. by prescription volume. Managing drug benefits for 100+ million members through Express Scripts. Cigna's employer-facing commercial insurance business has historically been more profitable than government-facing Medicare Advantage, making it more resilient than UNH or HUM during MA reimbursement pressure cycles.
Why Do Traders Watch CI?
CI has ATR of 2-3% and is the most defensively positioned large-cap health insurer. Its Evernorth PBM provides stable fee-based revenue regardless of medical cost trends. Post-earnings moves of 4-7% are typical. CI is less exposed to Medicare Advantage MLR pressure than UNH or HUM due to its commercial insurance focus. PBM regulatory risk (drug pricing reform) is the primary policy overhang.
Is CI a Buy Right Now? Current Signal Readings
Evernorth (Express Scripts + specialty pharmacy) generates 70%+ of Cigna's revenue and provides stable, fee-based earnings regardless of medical trend. When Evernorth's specialty pharmacy revenues accelerate. Driven by GLP-1, oncology, and gene therapy dispensing growth. CI's earnings become more predictable than any other large health insurer.
Cigna's commercial insurance business (employer health plans) is less exposed to Medicare Advantage reimbursement pressure than UNH or HUM. Giving CI more earnings stability during CMS rate cycles. When UNH and HUM fall on MA reimbursement concerns, CI typically declines less, making it a relative-value healthcare trade within the managed care sector.
CI's PBM-anchored earnings produce a more stable RSI range than pure insurance peers. RSI dips to 42-46 during broad healthcare selloffs. When CI's commercial insurance fundamentals are unchanged. Have been reliable entry points for 3-4 month holds as the market differentiates CI's defensive business mix from MA-heavy peers.
Congressional and FTC scrutiny of pharmacy benefit managers. Targeting spread pricing and formulary practices. Is the primary regulatory overhang for CI. Any legislation that caps PBM spread pricing or mandates pass-through pricing would materially impact Evernorth's profitability. Track Senate Finance Committee and FTC enforcement actions as the primary leading indicators.
📋 CI Key Stats for Traders
APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.
Analyze CI Free →